RVL Pharmaceuticals Investor Relations Material
Latest events
Q2 2023
RVL Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from RVL Pharmaceuticals PLC
Access all reports
RVL Pharmaceuticals PLC is a specialty pharmaceutical company that focuses on developing and commercializing products in the ocular and medical aesthetics sectors. Its main product, Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%), is FDA-approved for the treatment of acquired blepharoptosis, or low-lying eyelids, offering a non-surgical option for adults. The company serves underserved patient populations primarily in the United States and operates in several international markets. RVL Pharmaceuticals is headquartered in Bridgewater, New Jersey, and its shares are listed on the OTC Markets.
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
RVLP
Country
🇺🇸 United States